| 前收盘价格 | 82.96 |
| 成交量 | 1,902,530 |
| 预期市盈率 (P/E Forward) | 13.83 |
| 价格/销量 (P/S) | 3.67 |
| 股市价格/股市净资产 (P/B) | 10.19 |
| 52周波幅 | |
| 股息率 (DY TTM) | 2.81% |
| 营业毛利率 | 27.12% |
| 营业利益率 (TTM) | 38.11% |
| 稀释每股收益 (EPS TTM) | 5.56 |
| 季度收入增长率 (YOY) | 1.40% |
| 季度盈利增长率 (YOY) | 5.30% |
| 总债务/股东权益 (D/E MRQ) | 145.63% |
| 流动比率 (MRQ) | 1.74 |
| 营业现金流 (OCF TTM) | 2.94 B |
| 杠杆自由现金流 (LFCF TTM) | 2.30 B |
| 资产报酬率 (ROA TTM) | 15.11% |
| 股东权益报酬率 (ROE TTM) | 52.09% |
新闻情绪
正面
- ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up
- Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
负面
AIStockmoo 评分
| 价值 38% | -0.6 |
| AI Insight 参考 | NA |
| 相对估值 参考 | -2.1 |
| 财务健康 参考 | 1.7 |
| 时机 38% | 2.2 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 2.0 |
| 技术平均移动指标 参考 | 2.5 |
| 市场情绪 25% | 0.3 |
| 分析师共识 参考 | 0.0 |
| 新闻情绪 参考 | 1.1 |
| 聪明钱 | NA |
| 内部交易活动 参考 | NA |
| 机构资金流 参考 | NA |
| 市场环境 | ×0.85 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -4.0% |
| 支柱一致性 | ×1.06 |
| 不计入评分 | |
| 价格波动 参考 | -0.4 |
| 最终评分 | 0.62 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Zoetis Inc. | 混合的 | 看跌 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| ZTS | - | 2.81% | - | 10.19 |
| RDY | - | 0.68% | - | 3.07 |
| TAK | - | 4.61% | - | 1.43 |
| HLN | - | 2.14% | - | 1.84 |
| TEVA | - | - | - | 6.23 |
| HIMS | - | - | - | 18.72 |
|
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Mid Value |
| 内部持股比例 | 0.23% |
| 机构持股比例 | 96.61% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections. |
| 11 Nov 2026 | Yahoo Finance |
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
PARSIPPANY, N.J., November 11, 2026--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection. |
| 11 Nov 2026 | Yahoo Finance |
What Are Wall Street Analysts' Target Price for Zoetis Stock?
Despite significantly underperforming the broader market over the past year, Zoetis continues to receive a cautiously optimistic outlook from Wall Street analysts. |
| 10 Nov 2026 | Yahoo Finance |
Should You Buy Zoetis Stock At This Price?
For questions about this article or underlying research, email [email protected]. |
| 10 Nov 2026 | Yahoo Finance |
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
PARSIPPANY, N.J., November 10, 2026--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT. |
| 10 Nov 2026 | Yahoo Finance |
ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook
Animal health company Zoetis (NYSE:ZTS) beat Wall Street’s revenue expectations in Q3 2026, but sales fell by 1.3% year on year to $2.39 billion. The company expects the full year’s revenue to be around $9.27 billion, close to analysts’ estimates. Its non-GAAP profit of $1.75 per share was 15.8%… |
| 09 Nov 2026 | Yahoo Finance |
ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook
Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook. |
| 08 Nov 2026 | Yahoo Finance |
What Zoetis (ZTS) Said on Its Q3 Earnings Call
Zoetis (NYSE:ZTS) reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal health company narrowed its full-year revenue outlook to the high end of its previous range and rais… |
| 06 Nov 2026 | Yahoo Finance |
Zoetis (ZTS) Stock Price Drops After Q3 Earnings Margin Pressure
Zoetis came into this Q3 2026 earnings release with the stock up over the past month, then the mood flipped. The share price dropped about 3% on the first full trading day after results, a sharp move for a mature animal health business that investors often treat as a steady franchise. The headline… |
| 05 Nov 2026 | Yahoo Finance |
Zoetis: 3 Key Takeaways for Long-Term Investors
Fast lifecycle approvals, such as Simparica Duo, are how Zoetis plans to extend its core franchises beyond today's pressured pet care market. |
| 05 Nov 2026 | Yahoo Finance |
Zoetis (ZTS) Q3 2026 Earnings Call Transcript
Competitive pressure eased in dermatology, but clinic visits softened… |
| 05 Nov 2026 | Yahoo Finance |
No Greyhounds Here: Pet-Health Giant Zoetis Reverses 30% Monthlong Sprint
Zoetis stock reversed lower at the open Thursday after the pet health giant reported "generally fine" third-quarter metrics, an analyst said. |
| 05 Nov 2026 | Yahoo Finance |
ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up
Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products. |
| 05 Nov 2026 | Yahoo Finance |
Zoetis (ZTS) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
| 05 Nov 2026 | Yahoo Finance |
Zoetis (ZTS) Q3 Earnings and Revenues Top Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of +15.89% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 显示更多 | ||
| 股息率 (DY TTM) | 2.81% |
| 5年平均股息收益率 | 0.78% |
| 股息支付比率 | 32.24% |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 21 Apr 2025 | 06 Feb 2025 | 03 Jun 2025 | 0.5 现金 |
| 21 Jan 2025 | 12 Dec 2024 | 04 Mar 2025 | 0.5 现金 |
| 31 Oct 2024 | 10 Oct 2024 | 03 Dec 2024 | 0.432 现金 |
| 18 Jul 2024 | 22 May 2024 | 04 Sep 2024 | 0.432 现金 |
| 18 Apr 2024 | 06 Feb 2024 | 04 Jun 2024 | 0.432 现金 |
| 18 Jan 2024 | 07 Dec 2023 | 01 Mar 2024 | 0.432 现金 |
| 31 Oct 2023 | 12 Oct 2023 | 01 Dec 2023 | 0.375 现金 |
| 20 Jul 2023 | 11 May 2023 | 01 Sep 2023 | 0.375 现金 |
| 20 Apr 2023 | 08 Feb 2023 | 01 Jun 2023 | 0.375 现金 |
| 19 Jan 2023 | 08 Dec 2022 | 01 Mar 2023 | 0.375 现金 |
| 31 Oct 2022 | 13 Oct 2022 | 01 Dec 2022 | 0.325 现金 |
| 20 Jul 2022 | 19 May 2022 | 01 Sep 2022 | 0.325 现金 |
| 20 Apr 2022 | 08 Feb 2022 | 01 Jun 2022 | 0.325 现金 |
| 19 Jan 2022 | 07 Dec 2021 | 01 Mar 2022 | 0.325 现金 |
| 28 Oct 2021 | 14 Oct 2021 | 01 Dec 2021 | 0.25 现金 |
| 20 Jul 2021 | 20 May 2021 | 01 Sep 2021 | 0.25 现金 |
| 20 Apr 2021 | 10 Feb 2021 | 01 Jun 2021 | 0.25 现金 |
| 19 Jan 2021 | 09 Dec 2020 | 01 Mar 2021 | 0.25 现金 |
| 20 Oct 2020 | 07 Oct 2020 | 01 Dec 2020 | 0.2 现金 |
| 16 Jul 2020 | 20 May 2020 | 01 Sep 2020 | 0.2 现金 |
| 16 Apr 2020 | 11 Feb 2020 | 01 Jun 2020 | 0.2 现金 |
| 16 Jan 2020 | 12 Dec 2019 | 03 Mar 2020 | 0.2 现金 |
| 21 Oct 2019 | 04 Oct 2019 | 02 Dec 2019 | 0.164 现金 |
| 18 Jul 2019 | 16 May 2019 | 03 Sep 2019 | 0.164 现金 |
| 17 Apr 2019 | 13 Feb 2019 | 03 Jun 2019 | 0.164 现金 |
| 17 Jan 2019 | 13 Dec 2018 | 01 Mar 2019 | 0.164 现金 |
| 19 Nov 2018 | 11 Oct 2018 | 03 Dec 2018 | 0.126 现金 |
| 19 Jul 2018 | 16 May 2018 | 04 Sep 2018 | 0.126 现金 |
| 19 Apr 2018 | 13 Feb 2018 | 01 Jun 2018 | 0.126 现金 |
| 18 Jan 2018 | 11 Dec 2017 | 01 Mar 2018 | 0.126 现金 |
| 08 Nov 2017 | 05 Oct 2017 | 01 Dec 2017 | 0.105 现金 |
| 13 Jun 2017 | 11 May 2017 | 01 Sep 2017 | 0.105 现金 |
| 04 Apr 2017 | 14 Feb 2017 | 01 Jun 2017 | 0.105 现金 |
| 18 Jan 2017 | 06 Dec 2016 | 01 Mar 2017 | 0.105 现金 |
| 01 Nov 2016 | 06 Oct 2016 | 01 Dec 2016 | 0.095 现金 |
| 28 Jun 2016 | 12 May 2016 | 30 Aug 2016 | 0.095 现金 |
| 05 Apr 2016 | 19 Feb 2016 | 01 Jun 2016 | 0.095 现金 |
| 19 Jan 2016 | 16 Dec 2015 | 01 Mar 2016 | 0.095 现金 |
| 03 Nov 2015 | 01 Oct 2015 | 01 Dec 2015 | 0.083 现金 |
| 11 Aug 2015 | 21 Jul 2015 | 01 Sep 2015 | 0.083 现金 |
| 07 Apr 2015 | 27 Feb 2015 | 02 Jun 2015 | 0.083 现金 |
| 20 Jan 2015 | 17 Dec 2014 | 03 Mar 2015 | 0.083 现金 |
| 03 Nov 2014 | 02 Oct 2014 | 02 Dec 2014 | 0.072 现金 |
| 18 Aug 2014 | 31 Jul 2014 | 02 Sep 2014 | 0.072 现金 |
| 23 Apr 2014 | 26 Mar 2014 | 02 Jun 2014 | 0.072 现金 |
| 28 Jan 2014 | 19 Dec 2013 | 04 Mar 2014 | 0.072 现金 |
| 30 Oct 2013 | 12 Sep 2013 | 02 Dec 2013 | 0.065 现金 |
| 30 Jul 2013 | 20 Jun 2013 | 02 Sep 2013 | 0.065 现金 |
| 29 Apr 2013 | 28 Mar 2013 | 06 Jun 2013 | 0.065 现金 |
| 显示更多 | |||
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2025 | 1.00 | 2 | 0.80 |
| 2024 | 1.73 | 4 | 1.06 |
| 2023 | 1.50 | 4 | 0.76 |
| 2022 | 1.30 | 4 | 0.89 |
| 2021 | 1.00 | 4 | 0.41 |
| 2020 | 0.800 | 4 | 0.48 |
| 2019 | 0.656 | 4 | 0.50 |
| 2018 | 0.504 | 4 | 0.59 |
| 2017 | 0.420 | 4 | 0.58 |
| 2016 | 0.380 | 4 | 0.71 |
| 2015 | 0.332 | 4 | 0.69 |
| 2014 | 0.288 | 4 | 0.67 |
| 2013 | 0.195 | 3 | 0.60 |
| 显示更多 | |||
投资组合